Suresh Ramalingam
Overview
Explore the profile of Suresh Ramalingam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sagar S, Ramamoorthy P, Ramalingam S, Muthurajan R, Natarajan S, Doraiswamy U, et al.
Mol Biol Rep
. 2025 Mar;
52(1):298.
PMID: 40063283
Rice, a staple food for significant percent of the world's population, is increasingly vulnerable to drought stress, threatening global food security. This review synthesizes current knowledge on drought's physiological impact...
2.
Shu C, Li J, Rui J, Fan D, Niu Q, Bai R, et al.
Nat Commun
. 2025 Mar;
16(1):2324.
PMID: 40057483
Harnessing the power of immune system to treat cancer has become a core clinical approach. However, rewiring of intrinsic circuitry by genomic alterations enables tumor cells to escape immune surveillance,...
3.
Kalaiselvan E, Maiti S, Shivaramu S, Banu S, Sharun K, Mohan D, et al.
J Funct Biomater
. 2024 Mar;
15(3).
PMID: 38535259
Bone regeneration poses a significant challenge in the field of tissue engineering, prompting ongoing research to explore innovative strategies for effective bone healing. The integration of stem cells and nanomaterial...
4.
Valanparambil R, Lai L, Johns M, Davis-Gardner M, Linderman S, McPherson T, et al.
NPJ Vaccines
. 2023 Nov;
8(1):179.
PMID: 37990024
This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers...
5.
Kim D, Kim S, Camidge D, Shu C, Marrone K, Le X, et al.
J Thorac Oncol
. 2023 Jan;
18(5):650-656.
PMID: 36641093
Introduction: CD73 is overexpressed in EGFR-mutated NSCLC and may promote immune evasion, suggesting potential for combining CD73 blockers with EGFR tyrosine kinase inhibitors (TKIs). This phase 1b-2 study (NCT03381274) evaluated...
6.
Varlotto J, Sun Z, Ky B, Upshaw J, Fitzgerald T, Diehn M, et al.
Clin Lung Cancer
. 2022 Jul;
23(7):547-560.
PMID: 35882620
ECOG-ACRIN EA5181 is a current prospective, randomized trial that is investigating whether the addition of concomitant durvalumab to standard chemo/radiation followed by 1 year of consolidative durvalumab results in an...
7.
El Osta B, Carlisle J, Steuer C, Pakkala S, Leal T, Dhodapkar M, et al.
Clin Lung Cancer
. 2022 Jul;
23(7):e400-e404.
PMID: 35863963
Background: There is an urgent and unmet need for more effective treatment options for patients with metastatic and recurrent non-small-cell lung cancer (NSCLC) who progressed on platinum-based therapy, immune checkpoint...
8.
Valanparambil R, Carlisle J, Linderman S, Akthar A, Millett R, Lai L, et al.
J Clin Oncol
. 2022 Jun;
40(33):3808-3816.
PMID: 35759727
Purpose: To examine COVID-19 mRNA vaccine-induced binding and neutralizing antibody responses in patients with non-small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type [WT]) strain and variants of concern after...
9.
Varlotto J, Wang Y, Sun Z, Wakelee H, Ramalingam S, Schiller J
JTO Clin Res Rep
. 2022 Mar;
3(3):100274.
PMID: 35281954
Introduction: ECOG-ACRIN E1505 was a phase 3 randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with stages IB (>4 cm) to IIIA NSCLC. We sought to estimate...
10.
Kok P, Forde P, Hughes B, Sun Z, Brown C, Ramalingam S, et al.
BMJ Open
. 2022 Jan;
12(1):e057663.
PMID: 35078853
Introduction: There is a strong theoretical rationale for combining checkpoint blockade with cytotoxic chemotherapy in pleural mesothelioma and other cancers. Two recent single-arm, phase 2 trials [DuRvalumab with chEmotherapy as...